Skip to main content
Madeleine Cline headshot

Madeleine Cline

FSA, MAAA
Consulting Actuary
Brookfield, WI, US

Maddie Cline is a consulting actuary with the Milwaukee office of Milliman. She joined the firm in 2018.

バイオをダウンロードDownload

Experience

Maddie’s areas of expertise include Medicare Advantage and Part D, prescription drug analytics, and pharmaceutical manufacturer market access strategy.

Maddie has assisted Medicare Part D plans with bid preparation, formulary development, and strategic analyses. She leads Milliman-wide research in Medicare Part D formulary modeling and landscape analytics.

In the pharmacy space, Maddie has worked with pharmaceutical manufacturers, retail pharmacies, and industry organizations with an emphasis on the Medicare Part D benefit. Her most recent work includes helping various entities in the pharmacy supply chain understand the impacts of the Inflation Reduction Act.

Publications

Read their latest work

Article

Early 2025 Medicare Part D claims show continued increase in non-low income specialty drug spend

15 April 2025 - by Dominic Duke, Madeleine Cline, David M. Liner
Medicare Part D claims show non-low income drug spending rose 43% in early 2025 versus a year earlier, while costs for other categories also accelerated.
Article

MedIntel Insights: Early look at Medicare Prescription Payment Plan enrollment

15 April 2025 - by Dominic Duke, Madeleine Cline, David M. Liner
MedIntel Insights: We give an early glimpse of Medicare Prescription Payment Plan enrollment, which had 179,000 beneficiaries participate in its first two months.
Article

Part D Trend insights

15 April 2025 - by Madeleine Cline, Rachel W. Madden, Katherine M. Holcomb
In our latest trend report on Medicare Part D, we present a more detailed review of utilization and cost patterns in the individual market through year-end 2024.
Article

Part D trend insights: Initial snapshot of 2024 trends through Q3

03 February 2025 - by Madeleine Cline, Rachel W. Madden
We look at the top-line gross cost trends in Medicare Part D, focusing on factors that stakeholders should consider as they review 2024 prescription drug data.
Article

Prescribing a Part D formulary for the new IRA world

13 December 2024 - by Madeleine Cline, Justin Harris, Jian-ya Lin, Mark F. Gruenhaupt, RPh
Medicare Part D: We highlight the changes in plan incentives and key trends in 2025 formulary coverage, along with considerations for 2026.
Article

Demonstrations and consolidations: A first view of the 2025 PDP market

24 October 2024 - by Jake K. Klaisner, Madeleine Cline
Analyzing data from the Centers for Medicare and Medicaid Services, we highlight key changes in the prescription drug plan market for 2025.
Video

Breaking bid: What just happened?

18 September 2024 - by Emily Vandermause, Hayley M. Rogers, Jason Karcher, Madeleine Cline
The 2025 Medicare Advantage bid cycle has been one of the most tumultuous yet, as stakeholders took a stab at addressing significant changes to the risk models, the Inflation Reduction Act, significant Star Rating changes, bid resubmissions, unexpected PDP demonstrations, and potential regulatory uncertainty from the Supreme Court.
Article

Medicare price negotiation: Anchored drug prices in uncharted waters

05 September 2024 - by Katherine M. Holcomb, Madeleine Cline, Jake K. Klaisner, Jennifer Carioto, Gabriela Dieguez
We explore the implications of the 2026 maximum fair prices within Medicare price negotiation, part of a paradigm shift in Part D access and cost.
Article

Navigating new waters: How the Inflation Reduction Act alters government funding for Medicare Part D

06 August 2024 - by Madeleine Cline, David M. Liner
We discuss key drivers behind the increased direct subsidy for Medicare Part D due to the Inflation Reduction Act, along with implications for plan sponsors.
Article

Expected impact of Inflation Reduction Act Medicare Drug Price Negotiation Program on Medicare Part D beneficiary out-of-pocket costs

25 June 2024 - by Madeleine Cline, Michelle (Klein) Robb, Katherine M. Holcomb
We analyze the impact of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program on Part D beneficiary out-of-pocket costs.